Epic Pharma LLC announced the approval of its Abbreviated New Drug Application (ANDA) for generic drug **[Substance]** on October 27, 2005. This clearance positions Epic Pharma to capture market share from the branded reference product, capitalizing on the patent expiry while maintaining strict compliance with FDA regulations.